EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE Trial)

Ingelin Grov, Anne Relbo Authen, Satish Arora iD, Niklas Bergh, Katrine Rolid, Finn Gustafsson, Hans Eiskjær, Göran Rådegran, Einar Gude, Arne K Andreassen, Thea Halden, Kaspar Broch und 2 weitere

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70028 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Ingelin Grov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: Calcineurin Inhibitors, Everolimus, Heart Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcineurin inhibitors (CNIs) are associated with long‐term complications after heart transplantation (HTx). Everolimus (EVR)‐based immunosuppression allows for CNI withdrawal. We used data from The Scandinavian heart transplant everolimus de novo study with early CNI avoidance (SCHEDULE) trial to assess whether health‐related quality of life (HRQoL) differed between patients on long‐term treatment with EVR versus a CNI‐based regimen.

Methods

In SCHEDULE, we randomized 115 patients (mean age 51 ± 13 years, 27% women) to cyclosporine (CNI group; n = 59), or early introduction of EVR and cyclosporine withdrawal within 11 weeks of HTx (EVR group; n = 56). The primary endpoint was the glomerular filtration rate. We used the Short Form‐36 (SF‐36v2), the EuroQoL visual analogue scale (EQ VAS), and the Beck Depression Inventory (BDI) to assess HRQoL. We re‐evaluated the participants after 10–12 years.

Results

Seventy‐eight patients attended follow‐up at a median of 11 years after HTx. The SF‐36 physical component summary score increased from 32 ± 10 pre‐HTx to 44 ± 12 11 years after HTx ( p < 0.01) in the EVR group and from 33 ± 9 to 44 ± 11 ( p < 0.01) with CNI. The mental component summary score increased from 46 ± 12 to 53 ± 13 (EVR); p = 0.04 and from 38 ± 13 to 49 ± 13 (CNI); p < 0.01. Similar improvements were observed regarding EQ‐VAS and the BDI. There were no significant between‐group differences for either measure of HRQoL.

Conclusions

In heart transplant recipients, an EVR‐based immunosuppressive strategy resulted in similar long‐term improvements in HRQoL as treatment with a CNI‐based regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcineurin InhibitorsEverolimusHeart TransplantationImmunosuppressive AgentsAdultFemaleHumansMaleMiddle AgedFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalPostoperative ComplicationsPrognosisQuality of LifeRisk Factors

Stichwörter der Autor:innen

calcineurin inhibitorscyclosporineeverolimushealth‐related quality of lifeheart transplantationimmunosuppressionquality of life

Substanzen

Calcineurin InhibitorsEverolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Institute of Medicine, Sahlgrenska Academy University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • The Research Council of Norway, Lysaker, Norway.
  • Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Satish Arora, Lars Gullestad

Förderung

  • Novartis Norway

Zitieren

APA

Grov, I., Authen, A. R., Arora, S., Bergh, N., Rolid, K., Gustafsson, F., Eiskjær, H., Rådegran, G., Gude, E., Andreassen, A. K., Halden, T., Broch, K., Gullestad, L., & SCHEDULE investigators (2024). The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE Trial). Clinical Transplantation. https://doi.org/10.1111/ctr.70028

Vancouver

Grov I, Authen AR, Arora S, Bergh N, Rolid K, Gustafsson F, et al. The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE Trial). Clinical Transplantation. 2024. doi:10.1111/ctr.70028

BibTeX
@article{Grov2024,
  author = {Grov, Ingelin and Authen, Anne Relbo and Arora, Satish and Bergh, Niklas and Rolid, Katrine and Gustafsson, Finn and Eiskjær, Hans and Rådegran, Göran and Gude, Einar and Andreassen, Arne K and Halden, Thea and Broch, Kaspar and Gullestad, Lars and SCHEDULE investigators, SCHEDULE investigators},
  title = {The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE Trial)},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70028}
}
Kostenlos starten →